Vanda Pharmaceuticals Inc.
Company Stats
- Market Cap
- $296.9M
- as of Sep 30, 2026
- Shares Outstanding
- 60.5M
- Free Float
- 78.8%
Income Statement
- Revenue
- $216.1M
- Operating Income
- -$151.2M
- Net Income
- -$220.5M
- EBITDA
- -$150.1M
- Revenue Growth, 3Y
- -5.3%
- FCF Margin, 3Y Avg
- -17.6%
- FCF Margin, Worst Year
- -51.1%
Cash Flow
- Free Cash Flow
- -$110.4M
- FCF Yield
- -37.2%
- Owner FCF Yield
- -40.4%
Balance Sheet
- Cash & Equivalents
- $84.9M
Returns & Capital
- SBC, 3Y Avg
- $12.0M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $216.1M | -$110.4M | -51.1% |
| FY2024 | $198.8M | -$16.2M | -8.2% |
| FY2023 | $192.6M | $12.4M | 6.4% |
| FY2022 | $254.4M | $31.3M | 12.3% |
| FY2021 | $268.7M | $63.7M | 23.7% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 28, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Vanda, Herbalife, Tactile Launch Products; LENZ Adds VIZZ Telehealth
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back